Insurers accused of $50B fraud connected to Medicare Advantage plans

Private insurers who offer Medicare Advantage plans may have defrauded taxpayers to the tune of $50 billion between 2019 and 2021, a report from the Wall Street Journal shows. 

According to WSJ journalists, Medicare Advantage made “hundreds of thousands of questionable diagnoses that triggered extra taxpayer-funded payments,” including for deadly illnesses where patients received no care and for conditions that “people couldn’t possibly have.” 

The newspaper cites an analysis of billions of Medicare records for their determination. In some cases, neither the patient nor physicians seemed aware insurers were billing the Centers for Medicare and Medicaid Services (CMS) for the dubious services. 

Medicare Advantage plans are offered to seniors covered under Medicare for a premium, marketed as a way to expand the coverage of services and present them with more options. However, since their inception, these plans have been subject to scrutiny for denying necessary care while covering alternative therapies, like acupuncture, using a coordinated care reimbursement model. 

Despite being touted as advantageous, the upfront cost to enroll—given that coverage is largely determined by private insurers—may not add up to additional value for many patients. The number of patients covered by these plans has only gone up over time, and more than half of Medicare enrollees now utilize Advantage plans. 

The full story from the Wall Street Journal is available below.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”